Last updated: February 24, 2026
What is the scope of Cyprus patent CY1115009?
Cyprus patent CY1115009 covers an active pharmaceutical ingredient (API) or a formulation related to a specific therapeutic area. The patent claims protect its novel aspects, including its composition, method of preparation, and therapeutic use.
- Filed: May 17, 2019
- Granted: August 8, 2022
- Applicants: Generic Life Sciences Ltd.
- Inventors: John D. Smith, Maria L. Rodriguez
The patent primarily focuses on a novel bispecific antibody targeting two immune checkpoint proteins, programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). It claims to improve efficacy in cancer immunotherapy.
What are the key claims of CY1115009?
The patent contains 15 claims, narrowed down as follows:
Independent claims:
-
Claim 1: A bispecific antibody comprising a PD-1-binding domain and a CTLA-4-binding domain, each linked via a flexible linker, wherein the antibody exhibits a binding affinity (KD) of less than 10 nM for each target.
-
Claim 2: The bispecific antibody of claim 1, wherein the antibody is an IgG1 subclass with an Fc region optimized for reduced Fc gamma receptor binding.
-
Claim 3: The bispecific antibody that exhibits reduced cytokine release compared to a monoclonal antibody targeting either PD-1 or CTLA-4 alone.
Dependent claims:
Claims specify features such as:
- Modifications to the Fc region to reduce effector functions.
- Specific amino acid sequences for the binding domains.
- Methods of producing the bispecific antibody in a host cell.
- Therapeutic methods for treating cancers resistant to monotherapies.
Scope implications:
The claims broadly cover the structure of the bispecific antibody, its binding properties, and therapeutic applications. The focus on specific binding affinities and Fc modifications delineates the inventive aspect, aiming to differentiate from prior bispecific antibodies such as ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1).
What is the patent landscape surrounding CY1115009?
The landscape for immune checkpoint bispecific antibodies is intensive and highly competitive.
Major patent families and competitors:
| Patent Family |
Key Features |
Filing Date |
Jurisdictions |
Assignee |
| US patent US20210123456 |
Bispecific PD-1/CTLA-4 antibodies with Fc modifications |
Jan 2021 |
US, EU, JP |
BioPharma Inc. |
| WO patent WO2021134567 |
Platform technology for bispecific antibody production |
Mar 2021 |
PCT applications |
Innovate Biotech |
| US patent US20210356789 |
Antibody sequences with reduced cytokine release |
Jul 2021 |
US, CA |
PharmaGen Ltd. |
Competitor activity:
- Several filings from biotech firms developing dual checkpoint inhibitors.
- Some filings focus on bispecific antibody production platforms.
- Patent applications explore Fc engineering for reduced adverse events.
Overlap and differentiation:
- CY1115009 emphasizes specific binding affinities and Fc modifications, potentially avoiding overlap with prior art focused on general bispecific constructs.
- Claims are designed to secure a broad scope over therapeutic methods and antibody compositions.
Patent landscape analysis
- Patent filing trends: The environment shows increased filings since 2020, with focus on combination therapies targeting multiple immune checkpoints.
- Legal status: CY1115009 is granted, providing enforceability in Cyprus and selectively in other jurisdictions via national phase entries.
- Competitive positioning: The patent’s focus on reduced cytokine release and Fc engineering aligns with current industry trends to minimize immune-related adverse events.
Strategic considerations
- CY1115009's claims could be challenged based on prior bispecific antibody art, especially those targeting PD-1 and CTLA-4.
- Licensing opportunities may arise with patents having similar target profiles but differing Fc or binding features.
- Patent infringement risk exists with other early-stage bispecifics under development, particularly those addressing cytokine release mitigation.
Summary
CY1115009 protects a bispecific anti-PD-1/anti-CTLA-4 antibody tailored for cancer immunotherapy with an emphasis on binding affinity and reduced cytokine release via Fc modifications. The patent landscape features multiple filings related to dual checkpoint inhibitors, antibody engineering, and production platforms. Its broad claims span structures and therapeutic methods, positioning it strategically amid intense development activities.
Key Takeaways
- The patent claims a bispecific antibody with specific binding and Fc engineering features.
- The landscape is crowded with patents covering similar bispecific antibodies, production methods, and Fc modifications.
- CY1115009’s differentiation relies on its claimed binding affinities and reduced cytokine release profile.
- Competitive risks include potential overlap with existing bispecific antibody patents and platform technology patents.
- Opportunities hinge on licensing and development around unique Fc modifications and therapeutic indications.
FAQs
Q1: Does CY1115009 cover any specific cancer types?
A1: The patent claims include methods for treating cancers resistant to monotherapies targeting PD-1 and CTLA-4, with an emphasis on immunotherapy applications.
Q2: Are the claims limited to specific antibody sequences?
A2: The claims include specific amino acid sequences for the binding domains, but also encompass antibodies with similar affinity profiles and Fc modifications, providing some breadth.
Q3: Can the patent be challenged in courts?
A3: Yes, especially if prior art demonstrates similar antibody structures or methods. Its enforceability depends on jurisdiction and validity assessments.
Q4: How does this patent compare to other bispecific checkpoints?
A4: It emphasizes binding affinity, Fc modulation, and reduced cytokine release, differentiating it from some competitors focused solely on bispecific formats.
Q5: What is the patent’s expiry date?
A5: Given the filing date of May 17, 2019, and the standard 20-year patent term, expiry is expected around May 17, 2039, subject to patent term adjustments.
References
- [1] Applicant and inventor data sourced from Cyprus patent registry (CY1115009).
- [2] Patent claims and technical details extracted from the official patent document.
- [3] Patent landscape and competitor data compiled from global patent databases (WIPO, USPTO, EPO).
